MASH - Metabolic Dysfunction-Associated Steatohepatitis
Conditions
Keywords
Post-Liver Transplant, Cirrhosis, Metabolic dysfunction-associated steatohepatitis (MASH), MASLD, MASH, Liver
Brief summary
A Phase 2 double-blind, randomized, placebo-controlled study to evaluate resmetirom in 2 cohorts of subjects with moderate to advanced fibrosis, consistent with stage F2 and F3 fibrosis, who have undergone liver transplant. Cohort 1 will consist of patients who have undergone liver transplant for MASH cirrhosis who developed recurrent MASH. Cohort 2 will consist of subjects who have undergone liver transplant for indications other than MASH cirrhosis who developed de novo MASH.
Interventions
DRUGResmetirom
Randomized 80 or 100 mg
DRUGPlacebo
Placebo
Sponsors
Madrigal Pharmaceuticals, Inc.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Intervention model description
Randomized matching placebo
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. At least 12 months post-liver transplant at screening and meeting one of the following: * Cohort 1: Liver transplant for MASH cirrhosis with recurrent hepatic steatosis ≥8% by MRI-PDFF * Cohort 2: Liver transplant for non-MASH etiology with de novo hepatic steatosis ≥8% by MRI-PDFF 2. Presence of at least one metabolic risk factor, including overweight/obesity, dysglycemia or type 2 diabetes, hypertension or antihypertensive treatment, hypertriglyceridemia or low HDL cholesterol, or lipid-lowering therapy. 3. MASH with moderate to advanced liver fibrosis (F2-F3), confirmed by noninvasive fibrosis assessment (FibroScan and/or MRE) and a liver biopsy consistent with Stage F2/F3 MASH and no evidence of other liver pathology or graft rejection. 4. Stable renal function with estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m² prior to and during screening. 5. Stable liver enzymes at screening, without clinically significant worsening compared with recent historical values. 6. Stable immunosuppressive regimen for at least 3 months prior to screening. 7. Females of childbearing potential must have a negative pregnancy test, not be breastfeeding, and agree to use effective contraception during the study and for at least 30 days after the last dose; females not of childbearing potential are eligible.
Exclusion criteria
1. Participation in another interventional clinical trial with investigational drug exposure within 30 days (or 5 half-lives, whichever is longer) prior to screening. 2. Phosphatidylethanol (PEth) value of ≥20 ng/mL measured at screening or clinically significant alcohol use within 1 year prior to screening. 3. FibroScan VCTE \>20 kPa, a baseline biopsy demonstrating fibrosis consistent with F4, or MRE \> 5 kPa. 4. Uncontrolled or clinically significant thyroid disease, including active hyperthyroidism or untreated hypothyroidism. 5. Evidence of active liver disease other than MASH. 6. History of liver transplantation for an inborn error of metabolism. 7. Evidence of hepatic impairment or decompensation at screening. 8. Steroid resistant rejection of the transplanted liver or kidney, or a history of a rejection treated with high dose steroid within 3 months of screening. 9. Chronic rejection or chronic plasma-cell hepatitis. 10. Significant post-transplant vascular or biliary complications. 11. Significant cardiovascular or cerebrovascular disease within 6 months prior to randomization. 12. Uncontrolled hypertension at screening or randomization. 13. Current hepatocellular carcinoma. 14. Known human immunodeficiency virus (HIV) infection or other clinically significant immunocompromised state. 15. Any serious medical condition with a life expectancy of less than 5 years. 16. Current substance abuse or drug addiction. 17. Significant psychiatric, cognitive, or social conditions that would interfere with study participation or compliance, in the Investigator's judgment. 18. Known hypersensitivity to study drug or any of its excipients. 19. Use of prohibited concomitant medications that may affect liver function, steatosis, thyroid function, or study outcomes, or unstable doses of allowed metabolic therapies prior to randomization. 20. Use of statins above protocol-allowed doses or unstable lipid-lowering therapy prior to randomization. 21. Contraindications to MRI, including implanted devices incompatible with MRI, severe claustrophobia, or inability to undergo MRI procedures.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28 | 28 weeks | To determine the effect of MGL-3196/Resmetirom versus matching placebo on percent change from Baseline to Week 28 in hepatic fat fraction by magnetic resonance imaging proton density fat fraction (MRI-PDFF) in patients with baseline MRI-PDFF ≥8%. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| To evaluate the safety and tolerability of once-daily, oral administration of MGL-3196/resmetirom versus matching placebo in patients who have undergone a liver transplant | 52 weeks | — |
| 1.To determine the effect of MGL-3196/resmetirom versus matching placebo on liver stiffness as measured by FibroScan vibration controlled transient elastography (VCTE; kPa) | 28 and 52 Weeks | Absolute change and percent change from Baseline to Week 28 and Week 52 on FibroScan VCTE |
| 2. To determine the effect of MGL-3196/resmetirom versus matching placebo on serum lipid parameters | 28 and 52 Weeks | Absolute and percent change from Baseline to Week 28 and Week 52 in LDL-C, lipoprotein A \[Lp(a)\] in patients with baseline Lp(a) \>10 nmol/L and triglycerides (TGs) in patients with baseline TGs \>150 mg/dL |
| 3. To determine the effect of MGL-3196/resmetirom versus matching placebo on liver biochemistries | 28 and 52 weeks | Absolute and percent change from baseline in serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and gamma glutamyl transferase (GGT), at Week 28 and Week 52 |
Countries
Canada, United States
Contacts
CONTACTDavid Hernandez, MD
STUDY_DIRECTORTom Hare, MS
Madrigal Pharmaceuticals, Inc.
Outcome results
None listed